Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Ovarian Cancer Drug Half Way There

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Amgen (NASDAQ: AMGN  ) is half way there.

The biotech giant announced yesterday that its cancer drug trebananib combined with chemotherapy paclitaxel extended median progression-free survival in recurrent ovarian cancer patients by 1.8 months compared with paclitaxel alone. That may not seem like much, but the group that got paclitaxel alone only lasted 5.4 months before their disease progressed, so the extension of progression-free survival translates to a 34% reduction in the risk of disease progression.

But, of course, progression-free survival isn't what patients and their doctors really care about. They're more interested in overall survival than how long it takes for the disease to progress. The phase 3 clinical trial continues, but Amgen did give us a tidbit of information on how the secondary endpoint was proceeding.

"An early imbalance of deaths favoring the control arm was observed"


Amgen added that by the time the pre-planned interim analysis took place, the trend for overall survival was already in favor of trebananib.

It's possible these early deaths just happened randomly. But it's also feasible that trebananib has toxicity in some patients, but not all. Those patients die early in the study, but if there are enough patients that trebananib helps, the median overall survival trend could still be positive. Median overall survival isn't affected by the extremes -- like an arithmetic mean would be -- since the median focuses on how the middlemost patient in the study reacted to the drug and placebo.

The FDA won't ignore the early deaths, but without seeing the full data set -- which Amgen didn't release -- it's difficult to know whether they could hang up the approval. Considering that ovarian cancer is deadly already, Amgen is likely to get more leeway than a company would get for other diseases.

Amgen might be able to find a genetic marker that predicts whether the drug will help patients, like it's done with Vectibix and Bristol-Myers Squibb (NYSE: BMY  ) and Eli Lilly (NYSE: LLY  ) have done with Erbitux. Patients with mutations in a gene called KRAS don't respond to colon cancer drug Erbitux or Vectibix, so patients are routinely screened for the mutation. It cuts out some of the potential patients, but makes the drugs look better for the ones that take them.

And back to waiting
Amgen expects full overall survival data next year. The company didn't say, but I'd guess Amgen will wait for the overall survival data next year before applying to the FDA. A second phase 3 trial testing trebananib with another chemotherapy, which is expected to read out next April, should give investors -- and the FDA -- more confidence that the drug is helping ovarian cancer patients.

Dyax (UNKNOWN: DYAX.DL  ) and its investors will also be keeping a close eye on trebananib's development. The biotech helped Amgen discover trebananib and is due milestone payments for successful development of the drug.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2488271, ~/Articles/ArticleHandler.aspx, 9/29/2016 9:44:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.24 110.94 0.00%
S&P 500 2,167.70 -3.67 -0.17%
NASD 5,318.55 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
AMGN $169.71 Down -1.92 +0.00%
Amgen CAPS Rating: ****
BMY $55.09 Down -0.65 +0.00%
Bristol-Myers Squi… CAPS Rating: ****
DYAX.DL $0.00 Down +0.00 +0.00%
Dyax CAPS Rating: **
LLY $80.71 Down -0.17 +0.00%
Eli Lilly and Co. CAPS Rating: ***